A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections-Reference-Cited by-同舟云学术

A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections

Published:2012-05-30 Issue:1 Volume:7 Page:
ISSN:1746-1596
Container-title:Diagnostic Pathology
language:en
Short-container-title:Diagn Pathol

Author:

Nitta Hiroaki,Kelly Brian D,Padilla Mary,Wick Nikolaus,Brunhoeber Patrick,Bai Isaac,Singh Shalini,Ranger-Moore Jim,Bieniarz Chris,Tsuda Hitoshi,Grogan Thomas M

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1186/1746-1596-7-60.pdf

Reference26 articles.

1. Lee JA, Shaheen M, Walke T, Daly M: Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy. Expert Rev Pharmacoecon Outcome Res. 2011, 11: 325-341. 10.1586/erp.11.25.

2. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25: 118-145.

3. Madrid MA, Lo RW: Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER2-2/neu status. Breast Cancer Res. 2004, 6: R593-R600. 10.1186/bcr915.

4. Sauter G, Lee J, Barlett JMS, Slamon DJ, Press MF: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009, 27: 1324-1333.

5. Shah S, Chen B: Testing for HER2 in breast cancer: a continuing evolution. Patholog Res Int. 2011, 2011: 903202-

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. pHLIP-fused PD-L1 engages avelumab to elicit NK cytotoxicity under acidic conditions;Heliyon;2024-05

2. Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer;Medical Molecular Morphology;2024-04-15

3. HER2-low metastases of HER2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer;Frontiers in Oncology;2023-07-07

4. Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?;Expert Opinion on Therapeutic Targets;2023-05-04

5. Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma;Cancer Medicine;2023-04-29